IN2015DN02546A - - Google Patents
Info
- Publication number
- IN2015DN02546A IN2015DN02546A IN2546DEN2015A IN2015DN02546A IN 2015DN02546 A IN2015DN02546 A IN 2015DN02546A IN 2546DEN2015 A IN2546DEN2015 A IN 2546DEN2015A IN 2015DN02546 A IN2015DN02546 A IN 2015DN02546A
- Authority
- IN
- India
- Prior art keywords
- particles
- virus
- recombinant
- recombinant infectious
- infectious particles
- Prior art date
Links
- 239000002245 particle Substances 0.000 abstract 5
- 208000015181 infectious disease Diseases 0.000 abstract 4
- 241001502567 Chikungunya virus Species 0.000 abstract 3
- 230000002458 infectious effect Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 101710091045 Envelope protein Proteins 0.000 abstract 1
- 241000712079 Measles morbillivirus Species 0.000 abstract 1
- 101710188315 Protein X Proteins 0.000 abstract 1
- 102100021696 Syncytin-1 Human genes 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18444—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306176.4A EP2712871A1 (en) | 2012-09-27 | 2012-09-27 | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
| PCT/EP2013/070137 WO2014049094A1 (en) | 2012-09-27 | 2013-09-26 | Recombinant measles virus expressing chikungunya virus polypeptides and their applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN02546A true IN2015DN02546A (enExample) | 2015-09-11 |
Family
ID=46982495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2546DEN2015 IN2015DN02546A (enExample) | 2012-09-27 | 2013-09-26 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9655961B2 (enExample) |
| EP (2) | EP2712871A1 (enExample) |
| JP (1) | JP6251273B2 (enExample) |
| KR (1) | KR102077131B1 (enExample) |
| CN (1) | CN104918952B (enExample) |
| AU (1) | AU2013322635C1 (enExample) |
| BR (1) | BR112015006763B1 (enExample) |
| CA (1) | CA2884585C (enExample) |
| DK (1) | DK2900687T3 (enExample) |
| ES (1) | ES2682268T3 (enExample) |
| IN (1) | IN2015DN02546A (enExample) |
| MX (1) | MX359981B (enExample) |
| PH (1) | PH12015500499A1 (enExample) |
| PT (1) | PT2900687T (enExample) |
| SG (1) | SG11201502411PA (enExample) |
| WO (1) | WO2014049094A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI111811B (fi) * | 1998-06-05 | 2003-09-30 | Outokumpu Oy | Menetelmä kuivauksen tehostamiseksi |
| WO2016122414A1 (en) * | 2015-01-29 | 2016-08-04 | Agency For Science, Technology And Research | Nanocapsules carrying chikungunya-associated peptides |
| WO2017060360A1 (en) * | 2015-10-06 | 2017-04-13 | Invectys | Polyepitope constructs for use in immunotherapy |
| EP3184119A1 (en) | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
| WO2017221076A1 (en) | 2016-06-24 | 2017-12-28 | Institut Pasteur | Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases |
| CA3030451C (en) * | 2016-07-15 | 2023-09-05 | Etubics Corporation | Compositions and methods for alphavirus vaccination |
| KR101919403B1 (ko) * | 2016-11-04 | 2018-11-16 | 연세대학교 원주산학협력단 | 재조합 단백질 및 그의 용도 |
| EP3412307A1 (en) * | 2017-06-07 | 2018-12-12 | Institut Pasteur | Recombinant measles virus expressing zika virus proteins and their applications |
| CN118662621A (zh) * | 2017-09-21 | 2024-09-20 | 瓦尔尼瓦公司 | 包含免疫原性屈公病毒chikv-delta5nsp3的医药组成物的制备方法 |
| MX2020004833A (es) | 2017-11-09 | 2021-01-08 | Pasteur Institut | Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica. |
| WO2019156223A1 (ja) * | 2018-02-09 | 2019-08-15 | 国立大学法人大阪大学 | チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途 |
| EP3581646A1 (en) | 2018-06-15 | 2019-12-18 | Themis Bioscience GmbH | Integrated manufacturing and chromatographic system for virus production |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| EP3936517A1 (en) * | 2020-07-08 | 2022-01-12 | Institut Pasteur | An improved measles virus vaccine vector based on multiple tandem additional transcription units |
| CN115433741A (zh) * | 2022-06-23 | 2022-12-06 | 广西大学 | 盖他病毒为载体表达报告蛋白的重组病毒的构建方法 |
| CN117904059A (zh) * | 2022-10-17 | 2024-04-19 | 清华大学 | 一种基于麻疹病毒载体包装病毒样颗粒冠状病毒疫苗的方法 |
| KR102864666B1 (ko) * | 2025-04-21 | 2025-09-29 | 대한민국 | 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1375512B1 (en) | 2002-06-20 | 2009-07-22 | Institut Pasteur | Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions |
| CA2545597A1 (en) | 2006-03-15 | 2007-09-15 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| DK1939214T3 (da) | 2006-12-22 | 2013-10-14 | Pasteur Institut | Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira |
| EP2274442B1 (en) * | 2008-04-04 | 2016-06-29 | The Trustees Of The University Of Pennsylvania | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
| CN102317308A (zh) * | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
| WO2011082388A2 (en) | 2009-12-31 | 2011-07-07 | Medigen, Inc . | Infectious dna vaccines against chikungunya virus |
| WO2012106356A2 (en) * | 2011-01-31 | 2012-08-09 | GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | Virus-like particles and methods of use |
| CN102321639B (zh) * | 2011-09-08 | 2013-06-26 | 中国疾病预防控制中心病毒病预防控制所 | 基孔肯雅病毒病毒样颗粒的制备方法和应用 |
| MX357202B (es) * | 2012-02-16 | 2018-06-28 | Vlp Therapeutics Llc | Composicion de particula tipo virus. |
| US8961995B2 (en) * | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
-
2012
- 2012-09-27 EP EP12306176.4A patent/EP2712871A1/en not_active Withdrawn
-
2013
- 2013-09-26 CN CN201380055697.6A patent/CN104918952B/zh active Active
- 2013-09-26 IN IN2546DEN2015 patent/IN2015DN02546A/en unknown
- 2013-09-26 CA CA2884585A patent/CA2884585C/en active Active
- 2013-09-26 SG SG11201502411PA patent/SG11201502411PA/en unknown
- 2013-09-26 MX MX2015003717A patent/MX359981B/es active IP Right Grant
- 2013-09-26 AU AU2013322635A patent/AU2013322635C1/en active Active
- 2013-09-26 DK DK13771106.5T patent/DK2900687T3/en active
- 2013-09-26 JP JP2015533592A patent/JP6251273B2/ja active Active
- 2013-09-26 US US14/430,975 patent/US9655961B2/en active Active
- 2013-09-26 EP EP13771106.5A patent/EP2900687B1/en active Active
- 2013-09-26 ES ES13771106.5T patent/ES2682268T3/es active Active
- 2013-09-26 BR BR112015006763A patent/BR112015006763B1/pt active IP Right Grant
- 2013-09-26 WO PCT/EP2013/070137 patent/WO2014049094A1/en not_active Ceased
- 2013-09-26 KR KR1020157010848A patent/KR102077131B1/ko active Active
- 2013-09-26 PT PT137711065T patent/PT2900687T/pt unknown
-
2015
- 2015-03-09 PH PH12015500499A patent/PH12015500499A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2900687B1 (en) | 2018-05-02 |
| BR112015006763B1 (pt) | 2023-10-24 |
| US20150238592A1 (en) | 2015-08-27 |
| MX359981B (es) | 2018-10-18 |
| DK2900687T3 (en) | 2018-08-06 |
| AU2013322635B2 (en) | 2017-10-12 |
| EP2712871A1 (en) | 2014-04-02 |
| SG11201502411PA (en) | 2015-04-29 |
| MX2015003717A (es) | 2015-10-22 |
| ES2682268T3 (es) | 2018-09-19 |
| CN104918952B (zh) | 2019-01-22 |
| PT2900687T (pt) | 2018-08-06 |
| CA2884585C (en) | 2021-12-14 |
| HK1211951A1 (en) | 2016-06-03 |
| AU2013322635A1 (en) | 2015-04-02 |
| PH12015500499B1 (en) | 2015-04-27 |
| AU2013322635C1 (en) | 2018-02-08 |
| JP2015532090A (ja) | 2015-11-09 |
| US9655961B2 (en) | 2017-05-23 |
| JP6251273B2 (ja) | 2017-12-20 |
| WO2014049094A1 (en) | 2014-04-03 |
| KR20150058506A (ko) | 2015-05-28 |
| PH12015500499A1 (en) | 2015-04-27 |
| EP2900687A1 (en) | 2015-08-05 |
| KR102077131B1 (ko) | 2020-04-09 |
| CA2884585A1 (en) | 2014-04-03 |
| BR112015006763A2 (pt) | 2019-09-03 |
| CN104918952A (zh) | 2015-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500499A1 (en) | Recombinant measles virus expressing chikungunya virus polypeptides and their applications | |
| MX2015005505A (es) | Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano. | |
| MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| GB2513768A (en) | Complexes of cytomegalovirus proteins | |
| MX354516B (es) | Vectores que codifican el factor de viabilidad de conos derivado de bastones. | |
| PH12016502554B1 (en) | A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection | |
| MX350274B (es) | Vacunas para hsv-2. | |
| MX2019014674A (es) | Virus recombinante de sarampion que expresa proteinas de virus zika y sus aplicaciones. | |
| MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
| WO2016046234A3 (en) | Recombinant phe-free proteins for use in the treatment of phenylketonuria | |
| MY199929A (en) | Canine adenovirus vectors | |
| EP2525816A4 (en) | PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES | |
| ZA202003070B (en) | Lassa vaccine | |
| PH12017500450A1 (en) | Flavivirus virus like particle | |
| WO2016116905A9 (en) | Cmv antigens and uses thereof | |
| WO2012038832A3 (en) | Generation of replicating chimeric measles virus - retrovirus particles | |
| WO2013055326A3 (en) | Vaccines for human papilloma virus and methods for using the same | |
| MX358507B (es) | Antigenos vacunales quimericos contra el virus de la hepatitis c. | |
| WO2014060851A3 (en) | Hepatitis c virus immunogenic compositions and methods of use thereof | |
| EP2632942A4 (en) | RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND VACCINE CONTAINING THE SAME | |
| MX2015011485A (es) | Nuevas vacunas contra multiples subtipos del virus del dengue. | |
| WO2014151687A3 (en) | Compositions and methods to treat aids | |
| MX2015011064A (es) | Vacuna contra el virus de la leucemia bovina. | |
| WO2014152271A8 (en) | Viral proteins as immunomodulatory agents and vaccine components | |
| MY185444A (en) | Enterovirus 71 antiviral peptides |